Atorvastatin versus Placebo in ICU Patients with COVID-19 : Ninety-day Results of the INSPIRATION-S Trial
Thieme. All rights reserved..
BACKGROUND: In the INSPIRATION-S trial, atorvastatin versus placebo was associated with a nonsignificant 16% reduction in 30-day composite of venous/arterial thrombosis or death in intensive care unit (ICU) patients with COVID-19. Thrombo-inflammatory response in coronavirus disease 2019 (COVID-19) may last beyond the first 30 days.
METHODS: This article reports the effects of atorvastatin 20 mg daily versus placebo on 90-day clinical and functional outcomes from INSPIRATION-S, a double-blind multicenter randomized trial of adult ICU patients with COVID-19. The main outcome for this prespecified study was a composite of adjudicated venous/arterial thrombosis, treatment with extracorporeal membrane oxygenation (ECMO), or all-cause mortality. Functional status was assessed with the Post-COVID-19 Functional Scale.
RESULTS: In the primary analysis, 587 patients were included (age: 57 [Q1-Q3: 45-68] years; 44% women). By 90-day follow-up, the main outcome occurred in 96 (33.1%) patients assigned to atorvastatin and 113 (38.0%) assigned to placebo (hazard ratio [HR]: 0.80, 95% confidence interval [CI]: 0.60-1.05, p = 0.11). Atorvastatin in patients who presented within 7 days of symptom onset was associated with reduced 90-day hazard for the main outcome (HR: 0.60, 95% CI: 0.42-0.86, p interaction = 0.02). Atorvastatin use was associated with improved 90-day functional status, although the upper bound CI crossed 1.0 (ORordinal: 0.64, 95% CI: 0.41-1.01, p = 0.05).
CONCLUSION: Atorvastatin 20 mg compared with placebo did not significantly reduce the 90-day composite of death, treatment with ECMO, or venous/arterial thrombosis. However, the point estimates do not exclude a potential clinically meaningful treatment effect, especially among patients who presented within 7 days of symptom onset (NCT04486508).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:123 |
|---|---|
| Enthalten in: |
Thrombosis and haemostasis - 123(2023), 7 vom: 04. Juli, Seite 723-733 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
A0JWA85V8F |
|---|
| Anmerkungen: |
Date Completed 26.06.2023 Date Revised 26.06.2023 published: Print-Electronic ClinicalTrials.gov: NCT04486508 Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-2059-4844 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354496158 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354496158 | ||
| 003 | DE-627 | ||
| 005 | 20231226062340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/a-2059-4844 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354496158 | ||
| 035 | |a (NLM)36944357 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Talasaz, Azita H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Atorvastatin versus Placebo in ICU Patients with COVID-19 |b Ninety-day Results of the INSPIRATION-S Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.06.2023 | ||
| 500 | |a Date Revised 26.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04486508 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a BACKGROUND: In the INSPIRATION-S trial, atorvastatin versus placebo was associated with a nonsignificant 16% reduction in 30-day composite of venous/arterial thrombosis or death in intensive care unit (ICU) patients with COVID-19. Thrombo-inflammatory response in coronavirus disease 2019 (COVID-19) may last beyond the first 30 days | ||
| 520 | |a METHODS: This article reports the effects of atorvastatin 20 mg daily versus placebo on 90-day clinical and functional outcomes from INSPIRATION-S, a double-blind multicenter randomized trial of adult ICU patients with COVID-19. The main outcome for this prespecified study was a composite of adjudicated venous/arterial thrombosis, treatment with extracorporeal membrane oxygenation (ECMO), or all-cause mortality. Functional status was assessed with the Post-COVID-19 Functional Scale | ||
| 520 | |a RESULTS: In the primary analysis, 587 patients were included (age: 57 [Q1-Q3: 45-68] years; 44% women). By 90-day follow-up, the main outcome occurred in 96 (33.1%) patients assigned to atorvastatin and 113 (38.0%) assigned to placebo (hazard ratio [HR]: 0.80, 95% confidence interval [CI]: 0.60-1.05, p = 0.11). Atorvastatin in patients who presented within 7 days of symptom onset was associated with reduced 90-day hazard for the main outcome (HR: 0.60, 95% CI: 0.42-0.86, p interaction = 0.02). Atorvastatin use was associated with improved 90-day functional status, although the upper bound CI crossed 1.0 (ORordinal: 0.64, 95% CI: 0.41-1.01, p = 0.05) | ||
| 520 | |a CONCLUSION: Atorvastatin 20 mg compared with placebo did not significantly reduce the 90-day composite of death, treatment with ECMO, or venous/arterial thrombosis. However, the point estimates do not exclude a potential clinically meaningful treatment effect, especially among patients who presented within 7 days of symptom onset (NCT04486508) | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Atorvastatin |2 NLM | |
| 650 | 7 | |a A0JWA85V8F |2 NLM | |
| 700 | 1 | |a Sadeghipour, Parham |e verfasserin |4 aut | |
| 700 | 1 | |a Bakhshandeh, Hooman |e verfasserin |4 aut | |
| 700 | 1 | |a Sharif-Kashani, Babak |e verfasserin |4 aut | |
| 700 | 1 | |a Rashidi, Farid |e verfasserin |4 aut | |
| 700 | 1 | |a Beigmohammadi, Mohammad Taghi |e verfasserin |4 aut | |
| 700 | 1 | |a Moghadam, Keivan Gohari |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaian, Somaye |e verfasserin |4 aut | |
| 700 | 1 | |a Dabbagh, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Sezavar, Seyed Hashem |e verfasserin |4 aut | |
| 700 | 1 | |a Farrokhpour, Mohsen |e verfasserin |4 aut | |
| 700 | 1 | |a Abedini, Atefeh |e verfasserin |4 aut | |
| 700 | 1 | |a Aliannejad, Rasoul |e verfasserin |4 aut | |
| 700 | 1 | |a Riahi, Taghi |e verfasserin |4 aut | |
| 700 | 1 | |a Yadollahzadeh, Mahdi |e verfasserin |4 aut | |
| 700 | 1 | |a Lookzadeh, Somayeh |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaeifar, Parisa |e verfasserin |4 aut | |
| 700 | 1 | |a Matin, Samira |e verfasserin |4 aut | |
| 700 | 1 | |a Tahamtan, Ouria |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadi, Keyhan |e verfasserin |4 aut | |
| 700 | 1 | |a Zoghi, Elnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Rahmani, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini, Seyed Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Mousavian, Seyed Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Abri, Homa |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghipour, Pardis |e verfasserin |4 aut | |
| 700 | 1 | |a Baghizadeh, Elahe |e verfasserin |4 aut | |
| 700 | 1 | |a Rafiee, Farnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Jamalkhani, Sepehr |e verfasserin |4 aut | |
| 700 | 1 | |a Amin, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Mohebbi, Bahram |e verfasserin |4 aut | |
| 700 | 1 | |a Parhizgar, Seyed Ehsan |e verfasserin |4 aut | |
| 700 | 1 | |a Soleimanzadeh, Mahshid |e verfasserin |4 aut | |
| 700 | 1 | |a Aghakouchakzadeh, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Eslami, Vahid |e verfasserin |4 aut | |
| 700 | 1 | |a Payandemehr, Pooya |e verfasserin |4 aut | |
| 700 | 1 | |a Khalili, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Talakoob, Hamed |e verfasserin |4 aut | |
| 700 | 1 | |a Tojari, Taranom |e verfasserin |4 aut | |
| 700 | 1 | |a Shafaghi, Shadi |e verfasserin |4 aut | |
| 700 | 1 | |a Tabrizi, Sanaz |e verfasserin |4 aut | |
| 700 | 1 | |a Kakavand, Hessam |e verfasserin |4 aut | |
| 700 | 1 | |a Kashefizadeh, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Najafi, Atabak |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez, David |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Aakriti |e verfasserin |4 aut | |
| 700 | 1 | |a Madhavan, Mahesh V |e verfasserin |4 aut | |
| 700 | 1 | |a Sethi, Sanjum S |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Sahil A |e verfasserin |4 aut | |
| 700 | 1 | |a Monreal, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Hadavand, Naser |e verfasserin |4 aut | |
| 700 | 1 | |a Hajighasemi, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Ansarin, Khalil |e verfasserin |4 aut | |
| 700 | 1 | |a Maleki, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghian, Saeed |e verfasserin |4 aut | |
| 700 | 1 | |a Barco, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Siegerink, Bob |e verfasserin |4 aut | |
| 700 | 1 | |a Spatz, Erica S |e verfasserin |4 aut | |
| 700 | 1 | |a Piazza, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Kirtane, Ajay J |e verfasserin |4 aut | |
| 700 | 1 | |a Tassell, Benjamin W Van |e verfasserin |4 aut | |
| 700 | 1 | |a Lip, Gregory Y H |e verfasserin |4 aut | |
| 700 | 1 | |a Klok, Frederikus A |e verfasserin |4 aut | |
| 700 | 1 | |a Goldhaber, Samuel Z |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, Gregg W |e verfasserin |4 aut | |
| 700 | 1 | |a Krumholz, Harlan M |e verfasserin |4 aut | |
| 700 | 1 | |a Bikdeli, Behnood |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thrombosis and haemostasis |d 1979 |g 123(2023), 7 vom: 04. Juli, Seite 723-733 |w (DE-627)NLM000103896 |x 2567-689X |7 nnns |
| 773 | 1 | 8 | |g volume:123 |g year:2023 |g number:7 |g day:04 |g month:07 |g pages:723-733 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-2059-4844 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 123 |j 2023 |e 7 |b 04 |c 07 |h 723-733 | ||